OTC · Financial Statements
JW (Cayman) Therapeutics Co. Ltd (JWCTF) Financial Statements
$0.20
OTC: JWCTF
Market Cap $84.22M
Overview Financials Dividend JW (Cayman) Therapeutics Co. Ltd most recently reported annual revenue of $276.0M, net profit of $-541.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025 Revenue $31.0M $146.0M $174.0M $158.0M $276.0M Operating Profit $-759.0M $-856.0M $-790.0M $-459.0M $-242.0M Net Profit $-702.0M $-846.0M $-768.0M $-591.0M $-541.0M EPS $-1.76 $-2.06 $-1.87 $-1.43 $-1.33 Op Margin -2464.8% -587.4% -454.2% -290.3% -87.5%
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025 Total Assets $3.1B $2.8B $2.1B $1.7B $987.0M Total Liabilities $326.0M $437.0M $462.0M $511.0M $431.0M Cash $1.8B $1.4B $1.0B $757.0M $503.0M Borrowings $147.0M $279.0M $319.0M $422.0M $263.0M
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025 Operating Cash Flow $-561.0M $-537.0M $-398.0M $-333.0M $-77.0M Investing Cash Flow $-210.0M $-201.0M $-5.0M $-31.0M $-3.0M Financing Cash Flow $-18.0M $-23.0M $-27.0M $-28.0M $-25.0M Net Cash Flow $-796.0M $-451.0M $-377.0M $-249.0M $-254.0M Free Cash Flow $-634.0M $-614.0M $-413.0M $-349.0M $-78.0M
Valuation & Return Ratios
Metric Value PEG Ratio -0.16 EV / EBITDA -1.54 FCF Yield -13.61% Quick Ratio 1.29 Interest Coverage -58.05 Return 1Y -19.11% Return 3Y -43.83% Return 5Y —
Screens featuring this stock